| Aetna | Salivary Tests | 2025-10-01 |
| Aetna | Adoptive Immunotherapy and Cellular Therapy | 2025-10-01 |
| UHC Medicare Advantage | Durable Medical Equipment (DME), Prosthetics, Orthotics (Non-Foot Orthotics), Nutritional Therapy, and Medical Supplies Grid – Medicare Advantage Medical Policy | 2025-10-01 |
| UHC UMR Medical and Drug | Antiemetics for Oncology – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC UMR Medical and Drug | Encelto™ (Revakinagene Taroretcel-Lwey) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC UMR Medical and Drug | Lemtrada® (Alemtuzumab) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC UMR Medical and Drug | Long-Acting Injectable Antiretroviral Agents for HIV – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC UMR Medical and Drug | Medical Benefit Therapeutic Equivalent Medications - Excluded Drugs - Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC UMR Medical and Drug | Omvoh® (Mirikizumab-Mrkz) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC UMR Medical and Drug | Orencia® (Abatacept) Injection for Intravenous Infusion – Commercial Medical Benefit Drug Policy | 2025-10-01 |